News Related to Aldeyra Therapeutics

Related coverage linked through entity extraction aliases.

FDA Rejects Aldeyra's Reproxalap for Dry Eye Disease, Citing Inconsistent Trial Results

Mar 18, 2026

The FDA issued a complete response letter rejecting Aldeyra Therapeutics' reproxalap for dry eye disease, marking the third rejection in three years due to inconsistent trial results and lack of substantial evidence of efficacy.

FDA Decisions Expected in March 2026 for Multiple Biotech Drug Candidates

Feb 16, 2026

The FDA is set to announce decisions in March 2026 on several drug applications, including label expansions for approved therapies and new drug candidates, with some making repeat approval attempts.